In colon and gynecological cancers (endometrial, ovarian and triple negative breast cancers), it has been demonstrated that high glucocorticoid expression or glucocorticoid receptor (GR) activation are linked with cancer progression, development of treatment resistance, and/or a poorer patient prognosis [10,11,12,13,14,15]. Here, NR3C1 is linked to female reproductive organ cancer.